Loading...
Loading...
ACGN| Name | Value |
|---|---|
| Revenues | 4.8M |
| Cost of Revenue | 0.0M |
| Gross Profit | 4.8M |
| Operating Expense | 11.1M |
| Operating I/L | -8.9M |
| Other Income/Expense | -4.8M |
| Interest Income | 0.0M |
| Pretax | -11.1M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -10.8M |
Aceragen, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Their clinical development pipeline includes ACG-701, currently in Phase 2 clinical trials for cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801 for farber disease. Additionally, Aceragen has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
